AGENDA | pnh2025

Friday, September 26th 2025
Saturday, September 27th 2025

13.00 - 14.00

Lunch

14.00 - 14.15

Opening and welcome
Jarosław Czyż (Chair of the organising committee)
Antonio Risitano (Chair of the scientific committee)
Ewa Lech-Marańda (National Consultant in Hematology, Poland)
Krzysztof Giannopoulos (President of PTHiT, Poland)

14.15 - 15.35

SESSION 1: PNH overview
Chair: Jarosław Maciejewski, Antonio Risitano, Jens Panse

14.15 - 14.30

Natural history of PNH & Patophysiology
Jarosław Maciejewski

14.30 - 14.45

The fundamentals of IVH, EVH & BTH, including pharmacokinetic & pharmacodynamic BTH
Antonio Risitano

14.45 - 15.00

Thrombosis management in PNH
Richard Kelly

15.00 - 15.15

PNH & aplastic anaemia: an unmet need
Régis Peffault de Latour

15.15 - 15.35

Roundtable discussion

15.35 - 15.50

Coffee break

15.50 - 17.20

SESSION 2: C5 inhibition
Chair: Régis Peffault de Latour, Patrycja Mensah-Glanowska, Joanna Drozd-Sokołowska

15.50 - 16.10

C5 inhibition history, clinical trials on eculizumab and ravulizumab & real world evidence
Łukasz Szukalski

16.10 - 16.20

Case report: Challenging patient treated with ravulizumab
Delia Soare

16.20 - 16.25

Discussion

16.25 - 16.40

Battling with PNH from physician’s perspective
Barbara Pečovnik

16.40 - 16.45

Discussion

16.45 - 16.55

Case report: Challenging patient treated with crovalimab
Justyna Kozińska

16.55 - 17.00

Discussion

17.00 - 17.20

Crovalimab clinical trials data
Phillip Scheinberg

17.20 - 17.30

Coffee break

17.30 - 18.40

SESSION 3: PNH worldwide & varia
Chair: Agnieszka Piekarska, Anna Szmigielska-Kapłon, Jarosław Czyż

17.30 - 17.40

PNH in US & Canada
Jarosław Maciejewski

17.40 - 17.50

PNH in Western Europe
Jens Panse

17.50 - 18.00

PNH in Central-Eastern Europe
Jaroslav Čermák

18.00 - 18.10

Is there a place for alloHSCT in PNH?
Joanna Drozd-Sokołowska

18.10 - 18.35

PNH in Ukraine & discussion
Olena Kyselova

18.35 - 18.40

Day 1 wrap-up
Jarosław Czyż

19.30

Dinner

9.00 - 10.25

SESSION 4: Proximal complement inhibition
Chair: Richard Kelly, Phillip Scheinberg, Grzegorz Basak, Ana Boban

9.00 - 9.15

C3 inhibition: clinical trials and RWE on pegcetacoplan
Patrycja Mensah-Glanowska

9.15 - 9.30

Factor B inhibitor Iptacopan: clinical trials evidence
Régis Peffault de Latour

9.30 - 9.45

Factor D inhibitor Danicopan: clinical trials evidence
Jens Panse

9.45 - 10.00

Novel proximal inhibitors: MASP3 inhibitor clinical trial evidence
Bruno Fattizzo

10.00 - 10.25

Roundtable discussion

10.25 - 10.40

Coffee break

10.40 - 11.40

SESSION 5: Patient cases on proximal inhibitors
Chair: Jaroslav Čermák, Karla Rener, Bruno Fattizzo

10.40 - 10.55

Case report: Patient with EVH on C5 inhibitor treated with pegcetacoplan
Lenka Mastíková

10.55 - 11.00

Discussion

11.00 - 11.15

Case report: Patient treated with danicopan as an add-on to ravulizumab
Michał Kurlapski

11.15 - 11.20

Discussion

11.20 - 11.35

Case report: Patient treated with iptacopan monotherapy
Camilla Frieri

11.35 - 11.40

Discussion

11.40 - 12.00

Coffee break

12.00 - 12.30

Polish point of view: What therapeutic options do we have and what would we like to have?
Moderator: Łukasz Szukalski
Roundtable: Agnieszka Piekarska, Anna Szmigielska-Kapłon, Joanna Drozd-Sokołowska, Jarosław Czyż, Patrycja Mensah-Glanowska

12.30 - 13.35

SESSION 6: Registries & Mission

12.30 - 12.45

IPIG history and mission
Antonio Risitano

12.45 - 13.00

PNH Global Alliance mission
Izabela Kamieńska

13.00 - 13.15

IPIG registry
Richard Kelly

13.15 - 13.40

What do you want to know about PNH: Q&A session + discussion
Saturday panelists

13.40 - 13.50

Summary and conclusions
Jarosław Czyż, Antonio Risitano

13.50 - 14.50

Lunch